March 6, 2019

SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus

*

SynGEM shown to be safe and immunogenic in healthy adults

*

SynGEM the first non-replicating intranasal RSV subunit vaccine to induce persistent antibody responses in humans

Groningen, the Netherlands, March 6, 2019 – Virtuvax B.V. and the trustee of biotech company Mucosis B.V., Mr. Holtz LLM today announce the results of a first-in-human study of the intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM. The study was executed by Imperial College London. Results of the study have been posted (in press) on the website of the American Journal of...

Please reload

Virtuvax News

  • LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands